Cancer Genetics Inc. (CGIX)

1.10
NASDAQ : Health Services
Prev Close 1.20
Day Low/High 1.05 / 1.28
52 Wk Low/High 0.90 / 4.78
Avg Volume 640.80K
Exchange NASDAQ
Shares Outstanding 27.75M
Market Cap 33.30M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CANCER GENETICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cancer Genetics, Inc. To Contact The Firm

CANCER GENETICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Cancer Genetics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cancer Genetics, Inc.

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Cancer Genetics, Inc. Investors (CGIX)

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Cancer Genetics, Inc. Investors (CGIX)

Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Cancer Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIX

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Cancer Genetics, Inc. - CGIX

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Cancer Genetics, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Cancer Genetics, Inc. - CGIX

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Cancer Genetics, Inc. - CGIX

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cancer Genetics, Inc.

Cancer Genetics Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Strategic Business Updates

Cancer Genetics Reports Fourth Quarter And Full Year 2017 Financial Results And Provides Strategic Business Updates

Conference call at 4:30 p.m. EDT, Monday, April 2, 2018

Cancer Genetics To Host Fourth Quarter And Full Year 2017 Financial Results  

Cancer Genetics To Host Fourth Quarter And Full Year 2017 Financial Results  

Conference call at 4:30 p.m. EDT, Monday, April 2, 2018

Cancer Genetics To Participate In Upcoming Investor Conferences

Cancer Genetics To Participate In Upcoming Investor Conferences

LD Micro Main Event and Benchmark Micro Cap Conference

Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann To Its Board Of Directors

Cancer Genetics Appoints Renowned Biotech Entrepreneur Dr. Thomas F. Widmann To Its Board Of Directors

Founder of Multiple Successful Biotech Companies Including Actelion Pharmaceuticals, Sold to Johnson & Johnson for $30 Billion

Cancer Genetics Reports Record Third Quarter 2017 Revenue And 134% Increase In Contracted Bookings From Major Biotech And Pharmaceutical Companies

Cancer Genetics Reports Record Third Quarter 2017 Revenue And 134% Increase In Contracted Bookings From Major Biotech And Pharmaceutical Companies

Company Also Increased Number of Clinical Trials and Studies it Supports to 191, up 59%

Cancer Genetics, Inc. To Host Conference Call To Discuss Strategic And Business Rationale Of vivoPharm Acquisition

Cancer Genetics, Inc. To Host Conference Call To Discuss Strategic And Business Rationale Of vivoPharm Acquisition

Conference call scheduled for Tuesday, August 22, 2017- 8:30 AM Eastern

TheStreet Quant Rating: D- (Sell)